ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

ClinicalTrials.gov ID: NCT03272217

Public ClinicalTrials.gov record NCT03272217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer

Study identification

NCT ID
NCT03272217
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arjun Balar, MD
Other
Enrollment
16 participants

Conditions and interventions

Interventions

  • Atezolizumab Drug
  • Bevacizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 12, 2017
Primary completion
May 26, 2021
Completion
Mar 16, 2022
Last update posted
Jan 6, 2025

2017 – 2022

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
University of Arizona at Dignity Health St. Joseph Phoenix Arizona 85004
Rush University Medical Center Chicago Illinois 60612
HealthPartners Institute Minneapolis Minnesota 55440
New York University Clinical Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Cleveland Clinic Cleveland Ohio 44195
West Cancer Center University of Tennessee Memphis Tennessee 38120
Froedtert & The Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03272217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2025 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03272217 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →